Does Georgia Medicaid Cover Wegovy or Zepbound? No, Except a Narrow Teen Route

No. As of November 2026, Georgia Medicaid does not cover Wegovy, Zepbound or any other drug for weight loss in adults: its state plan excludes weight-loss agents, and neither Wegovy nor Zepbound appears on its November 2026 drug list.^[1][5] The one exception is narrow: teenagers aged 12 to 17 who have high cholesterol and already take a cholesterol drug can get Xenical or Saxenda with prior authorization.^[2]

Will Georgia Medicaid pay for Wegovy or Zepbound to lose weight?

It does not. Federal law gives each state the option to leave weight-loss drugs out of Medicaid.^[9] Georgia takes it: the drug section of its state plan, in the version CMS approved in June 2024, names drugs for weight loss, weight gain and anorexia among the categories it excludes.^[5]

The drug list matches. The November 2026 list has rows for Ozempic, Mounjaro and other diabetes drugs, but none for Wegovy, Zepbound or Foundayo, and the state’s cross-reference of prior authorization criteria has no entry for them either.^[1][4] The list itself notes that it does not name every covered drug, so absence alone would not settle the matter.^[1] Together with the state plan exclusion, it does. Our explainer on why Medicaid covers Ozempic but often not Wegovy explains the federal rules behind this split.

Is there a Georgia route for heart disease, sleep apnea or MASH?

Not on the state’s list. Wegovy carries FDA approval for cutting the odds of heart attack and stroke and for the liver disease MASH, and Zepbound carries one for sleep apnea in adults with obesity.^[11][12] Several states now cover those uses even while refusing weight loss, including neighboring Alabama, which opened all three. Georgia has no criteria for any of them, because neither drug has a place on its list.^[1][4]

People with type 2 diabetes have a partial workaround. Georgia’s Ozempic criteria include its own heart route: an adult with diabetes, an HbA1c of 6.5% or higher and established cardiovascular disease can be approved to cut the odds of major heart events.^[3] Ozempic and Wegovy contain the same drug, semaglutide, at different doses.

Does Georgia Medicaid cover Ozempic and Mounjaro for diabetes?

Yes, and the preferred list is broad. Ozempic, Mounjaro, Victoza and a generic liraglutide are preferred; each still needs prior authorization, and Rybelsus and Trulicity are non-preferred.^[1] The criteria ask for a type 2 diabetes diagnosis with an HbA1c of 6.5% or higher, and Mounjaro can be approved from age 10.^[3] Ozempic also has criteria for slowing kidney decline in diabetes-related kidney disease.^[3]

Coverage for diabetes does not stretch to weight loss. The criteria tie each approval to blood sugar control, kidney protection or heart risk in a person with diabetes, so a request for weight loss alone on Ozempic or Mounjaro falls outside them.^[3]

Can a Georgia teenager get Saxenda through Medicaid?

Only in a narrow case. Georgia files Saxenda and Xenical under cholesterol drugs, and both are covered only from age 12 through 17.^[1][2] The teen must have high cholesterol or high blood fats and already be taking a cholesterol-lowering drug, along with diet and activity changes.^[2] Xenical is the preferred first step, at a BMI of 27 or more. Saxenda needs a BMI of 30 or more, a weight over 60 kg and a Xenical trial that failed or could not be tolerated.^[2] Approvals last a year.^[2]

That is far narrower than the Saxenda label, which covers any teen from 12 with obesity who weighs more than 60 kg.^[10] Wegovy, which is also approved from age 12, has no teen route in Georgia at all.^[11][1] The criteria were last revised in July 2021 and do allow exceptions to be considered through prior authorization, so a prescriber with a strong case can ask.^[2] Our review of GLP-1 drugs in teenagers covers the evidence, and our orlistat review covers Xenical.

Do Georgia’s Medicaid managed care plans cover more?

Probably not, but check. The state’s prior authorization guide says its rules do not apply to the care management organization (CMO) plans, which run their own approval processes and criteria.^[6] Their criteria for weight-loss drugs were not all published where we could read them. A member of a CMO should ask the plan directly and get the answer in writing.

For fee-for-service members, OptumRx handles requests for the state: by phone at 1-866-525-5827, by fax at 1-888-491-9742, or through CoverMyMeds.^[6] Requests are reviewed within 24 hours, and the guide warns that a bare statement of medical necessity counts as insufficient.^[6]

How do you appeal a denial in Georgia?

An appeal has little to work with when the only diagnosis is obesity, since the state plan excludes that use.^[5] Appeals make sense for a diabetes drug denied for missing records, or for a teen whose file meets the cholesterol criteria.

In fee-for-service, a prescriber appeal goes in writing to fax 1-877-239-4565 and is answered within 72 hours.^[6] A member’s own fair hearing deadline is printed on the notice, and federal rules cap it at 90 days from the mailing date.^[8] In a CMO the steps differ. Peach State, for example, gives members 60 days from a denial notice to appeal to the plan and 120 days from the plan’s decision to request a state fair hearing.^[7] Our guide to prior authorization and appeals explains how to build the file, and the Georgia state page summarizes the Medicaid facts.

What can you do if Georgia Medicaid won’t pay?

Paying cash is the main route, and manufacturer copay cards are not available to Medicaid members; Lilly’s card terms rule them out.^[13] In the prices we track, Novo Nordisk sells most Wegovy pen doses for $349 a month to self-pay patients, and Lilly’s Zepbound KwikPen runs from $299 at the starting dose to $449 at higher doses refilled on time.^[13][14] Check each program’s terms on government coverage first, and see our comparison of the cheapest options without insurance.